Core Viewpoint - The article discusses the significant transformation in the veterinary medicine industry in China, driven by the reduction and replacement of antibiotics in animal husbandry, alongside the rising demand for pet healthcare products, highlighting investment opportunities in the biological veterinary drug sector [3][4][5]. Group 1: Antibiotic Reduction and Replacement - The veterinary medicine industry is crucial for ensuring animal health and disease prevention, which in turn stabilizes the supply of meat and eggs [4]. - Historically, the industry relied heavily on antibiotics, leading to increased antibiotic resistance and environmental contamination [4][5]. - Since 2020, China has implemented strict regulations to phase out growth-promoting antibiotics, promoting the development of alternative products [5][6]. Group 2: Current Status of Biological Veterinary Drugs - Biological veterinary drugs, including vaccines and microbial preparations, are becoming essential for sustainable animal husbandry and food safety [6][7]. - Vaccines are the most significant category within biological veterinary drugs, preventing infectious diseases and reducing the need for antibiotics [6][7]. - The development of innovative veterinary drugs in China has lagged behind due to market preferences for cheaper, traditional solutions [8][9]. Group 3: Investment Dynamics - The rise of pet culture has led to increased investment in the veterinary drug sector, particularly in pet healthcare products [9][12]. - The Chinese pet medical market is projected to reach 94 billion yuan by 2024, indicating a growing focus on pet pharmaceuticals [9]. - Recent financing activities in the biological veterinary drug sector have primarily occurred in early to mid-stage investments, with significant interest in pet vaccines and alternative antibiotic products [12][13].